Reasons for Discontinuation of Obesity Pharmacotherapy With Semaglutide or Tirzepatide in Clinical Practice
Obesity · 2025-12 · 33 (12) · 2296-2303
DOI: 10.1002/oby.70058 ↗At a glance
Journal article in Obesity, published online on 2025-10-02. Written by Hamlet Gasoyan and 9 co-authors. Institution: Center for Value-Based Care Research, Department of Internal Medicine and Geriatrics, Primary Care Institute, Cleveland Clinic, Cleveland, Ohio, USA. Major MEDLINE topics: Glucagon-Like Peptides, Obesity, Tirzepatide, Anti-Obesity Agents. Cited 50 times so far (Crossref); 35 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: Cleveland Clinic Research Program Committees.
Abstract (original language)
Objective
This study aimed to characterize the reasons for treatment discontinuation with injectable semaglutide or tirzepatide for obesity in regular clinical practice.
Methods
This cross‐sectional study used electronic health record data between January 2022 and December 2024 from a single integrated health system in Ohio and Florida. The primary reason for treatment discontinuation was examined in a randomly selected sample of adults with overweight or obesity and without type 2 diabetes who initiated injectable semaglutide or tirzepatide and discontinued treatment within the first year.
Results
We randomly selected 288 patients; 145 received semaglutide and 143 tirzepatide. Overall, 137 patients (47.6%) discontinued their medication due to cost or insurance‐related issues, 42 (14.6%) due to inability to tolerate the side effects, 34 (11.8%) as they were unable to fill the medication due to shortages, 7 (2.4%) as they switched to a compounded medication, and 5 (1.7%) due to unsatisfactory weight loss; 31 (10.8%) discontinued for other reasons, and for 32 (11.1%) patients the discontinuation reason was not specified in the electronic health record.
Conclusions
High cost or insurance‐related issues are the most common reasons for treatment discontinuation with semaglutide or tirzepatide for obesity. Our findings highlight the need for policies to address cost and could inform discussions between healthcare providers and patients concerning cost and side effects.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Center for Value-Based Care Research, Department of Internal Medicine and Geriatrics, Primary Care Institute, Cleveland Clinic, Cleveland, Ohio, USA.
- Department of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.
- Department of Surgery, Bariatric and Metabolic Institute, Cleveland Clinic, Cleveland, Ohio, USA.
- Department of Internal Medicine and Geriatrics, Primary Care Institute, Cleveland Clinic, Cleveland, Ohio, USA.
- Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio, USA.
ORCID profiles: Hamlet Gasoyan, W Scott Butsch
Funding
- Cleveland Clinic Research Program Committees
Cite
APA
Gasoyan, H., Butsch, W. S., Casacchia, N. J., Schulte, R., Criswell, V., Fox, J., Renner, H., Le, P., Alpert, J., & Rothberg, M. B. (2025). Reasons for Discontinuation of Obesity Pharmacotherapy With Semaglutide or Tirzepatide in Clinical Practice. Obesity, 33(12), 2296-2303. https://doi.org/10.1002/oby.70058
Vancouver
Gasoyan H, Butsch WS, Casacchia NJ, Schulte R, Criswell V, Fox J, et al. Reasons for Discontinuation of Obesity Pharmacotherapy With Semaglutide or Tirzepatide in Clinical Practice. Obesity. 2025;33(12):2296-2303. doi:10.1002/oby.70058
BibTeX
@article{Gasoyan2025,
author = {Gasoyan, Hamlet and Butsch, W Scott and Casacchia, Nicholas J and Schulte, Rebecca and Criswell, Victoria and Fox, Jacqueline and Renner, Holly and Le, Phuc and Alpert, Jordan and Rothberg, Michael B},
title = {Reasons for Discontinuation of Obesity Pharmacotherapy With Semaglutide or Tirzepatide in Clinical Practice},
journal = {Obesity},
year = {2025},
volume = {33},
number = {12},
pages = {2296--2303},
doi = {10.1002/oby.70058}
}
EUVIMED